Acute myeloid leukemia (AML) with mutated NPM1 usually carries normal karyotype (NK), but it may harbor chromosomal aberrations whose significance remains unclear. We addressed this question in 631 AML patients with mutated/cytoplasmic NPM1. An abnormal karyotype (AK) was present in 93 of 631 cases (14.7%), the most frequent abnormalities being +8, +4, -Y, del(9q), +21. Chromosome aberrations in NPM1-mutated AML were similar to, but occurred less frequently than additional chromosome changes found in other AML with recurrent cytogenetic abnormalities according to WHO classification. Four of the 31 NPM1-mutated AML patients karyotyped at different time points had NK at diagnosis but AK at relapse: del(9q) (n = 2), t(2;11) (n = 1), inv(12) (n = 1). NPM1-mutated AML with NK or AK showed overlapping morphologic, immunophenotypic (CD34 negativity), and gene expression profile (down-regulation of CD34 and up-regulation of HOX genes). No difference in survival was observed among NPM1-mutated AML patients independently of whether they carried a NK or an AK, the NPM1-mutated/FLT3-ITD negative cases showing the better prognosis. Findings in our patients point to chromosomal aberrations as secondary events, reinforce the concept that NPM1 mutation is a founder genetic lesion, and indicate that NPM1-mutated AML should be clinically handled as one entity, irrespective of the karyotype. (Blood. 2009; 114: 3024-3032)

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features / C., Haferlach; C., Mecucci; S., Schnittger; A., Kohlmann; M., Mancini; A., Cuneo; N., Testoni; G., Rege Cambrin; A., Santucci; Vignetti, Marco; P., Fazi; M. P., Martelli; T., Haferlach; B., Falini. - In: BLOOD. - ISSN 0006-4971. - 114:14(2009), pp. 3024-3032. [10.1182/blood-2009-01-197871]

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features

VIGNETTI, Marco;
2009

Abstract

Acute myeloid leukemia (AML) with mutated NPM1 usually carries normal karyotype (NK), but it may harbor chromosomal aberrations whose significance remains unclear. We addressed this question in 631 AML patients with mutated/cytoplasmic NPM1. An abnormal karyotype (AK) was present in 93 of 631 cases (14.7%), the most frequent abnormalities being +8, +4, -Y, del(9q), +21. Chromosome aberrations in NPM1-mutated AML were similar to, but occurred less frequently than additional chromosome changes found in other AML with recurrent cytogenetic abnormalities according to WHO classification. Four of the 31 NPM1-mutated AML patients karyotyped at different time points had NK at diagnosis but AK at relapse: del(9q) (n = 2), t(2;11) (n = 1), inv(12) (n = 1). NPM1-mutated AML with NK or AK showed overlapping morphologic, immunophenotypic (CD34 negativity), and gene expression profile (down-regulation of CD34 and up-regulation of HOX genes). No difference in survival was observed among NPM1-mutated AML patients independently of whether they carried a NK or an AK, the NPM1-mutated/FLT3-ITD negative cases showing the better prognosis. Findings in our patients point to chromosomal aberrations as secondary events, reinforce the concept that NPM1 mutation is a founder genetic lesion, and indicate that NPM1-mutated AML should be clinically handled as one entity, irrespective of the karyotype. (Blood. 2009; 114: 3024-3032)
acute; antigens; cd34; chromosome aberrations; fms-like tyrosine kinase 3; gene expression profiling; gene expression regulation; genetics; genetics/immunology/pathology; genetics/metabolism; homeodomain proteins; humans; immunophenotyping; karyotyping; leukemia; leukemic; messenger; metabolism; mutation; myeloid; nuclear proteins; oligonucleotide array sequence analysis; prognosis; reverse transcriptase polymerase chain reaction; rna
01 Pubblicazione su rivista::01a Articolo in rivista
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features / C., Haferlach; C., Mecucci; S., Schnittger; A., Kohlmann; M., Mancini; A., Cuneo; N., Testoni; G., Rege Cambrin; A., Santucci; Vignetti, Marco; P., Fazi; M. P., Martelli; T., Haferlach; B., Falini. - In: BLOOD. - ISSN 0006-4971. - 114:14(2009), pp. 3024-3032. [10.1182/blood-2009-01-197871]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/396583
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 49
  • Scopus 137
  • ???jsp.display-item.citation.isi??? 119
social impact